Alvin H. Schmaier

Alvin H. Schmaier's AcademicInfluence.com Rankings

Alvin H. Schmaier

Physics

#6627

World Rank

#8595

Historical Rank

physics Degrees

Download Badge

Physics

Alvin H. Schmaier's Degrees

PhD Physics University of California, Berkeley
Masters Physics University of California, Berkeley
Bachelors Physics University of California, Berkeley

Why Is Alvin H. Schmaier Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Alvin H. Schmaier's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. (1997) (573)
Enzymes and Receptors of Prostaglandin Pathways with Arachidonic Acid-derived Versus Eicosapentaenoic Acid-derived Substrates and Products*♦ (2007) (397)
Recommendations for the standardization of light transmission aggregometry: a consensus of the working party from the platelet physiology subcommittee of SSC/ISTH (2013) (394)
In vivo roles of factor XII. (2010) (314)
Protease nexin-II (amyloid beta-protein precursor): a platelet alpha-granule protein. (1990) (280)
Identification and Characterization of Prolylcarboxypeptidase as an Endothelial Cell Prekallikrein Activator* (2002) (257)
The contact activation and kallikrein/kinin systems: pathophysiologic and physiologic activities (2016) (252)
Use of factor IX complex in warfarin-related intracranial hemorrhage. (1999) (229)
High molecular weight kininogen regulates prekallikrein assembly and activation on endothelial cells: a novel mechanism for contact activation. (1998) (180)
The expression of high molecular weight kininogen on human umbilical vein endothelial cells. (1988) (179)
Endothelial Kruppel-like factor 4 protects against atherothrombosis in mice. (2012) (178)
The kallikrein-kinin and the renin-angiotensin systems have a multilayered interaction. (2003) (177)
Identification of cytokeratin 1 as a binding protein and presentation receptor for kininogens on endothelial cells. (1998) (176)
Anti-c5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis. (2002) (176)
Factor XII interacts with the multiprotein assembly of urokinase plasminogen activator receptor, gC1qR, and cytokeratin 1 on endothelial cell membranes. (2002) (167)
Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors. A report of four cases. (2000) (157)
D-dimer, P-selectin, and microparticles: Novel markers to predict deep venous thrombosis (2004) (152)
Deletion of murine kininogen gene 1 (mKng1) causes loss of plasma kininogen and delays thrombosis. (2007) (146)
Platelet aggregation testing in platelet-rich plasma: description of procedures with the aim to develop standards in the field. (2005) (143)
Prolylcarboxypeptidase regulates food intake by inactivating alpha-MSH in rodents. (2009) (142)
The elusive physiologic role of Factor XII. (2008) (139)
Factor XII: what does it contribute to our understanding of the physiology and pathophysiology of hemostasis & thrombosis. (2010) (132)
Mapping the Cell Binding Site on High Molecular Weight Kininogen Domain 5 (*) (1995) (131)
The effect of high molecular weight kininogen on surface-adsorbed fibrinogen. (1984) (131)
Increased Platelet and Microparticle Activation in HIV Infection: Upregulation of P-Selectin and Tissue Factor Expression (2012) (128)
Recombinant prolylcarboxypeptidase activates plasma prekallikrein. (2004) (123)
Platelet Aggregation Testing in Platelet-Rich Plasma (2005) (122)
Detection of amide I signals of interfacial proteins in situ using SFG. (2003) (121)
The plasma kallikrein-kinin system counterbalances the renin-angiotensin system. (2002) (119)
Expression and colocalization of cytokeratin 1 and urokinase plasminogen activator receptor on endothelial cells. (2001) (115)
Bradykinin and its metabolite, Arg-Pro-Pro-Gly-Phe, are selective inhibitors of alpha-thrombin-induced platelet activation. (1996) (115)
Identification of an endothelial cell binding site on kininogen domain D3. (1995) (113)
Platelet-derived S100 family member myeloid-related protein-14 regulates thrombosis. (2014) (112)
Protease nexin-2/amyloid beta protein precursor. A tight-binding inhibitor of coagulation factor IXa. (1993) (108)
Factor XII stimulates ERK1/2 and Akt through uPAR, integrins, and the EGFR to initiate angiogenesis. (2009) (107)
Human neutrophils contain and bind high molecular weight kininogen. (1989) (104)
High molecular weight kininogen binds to unstimulated platelets. (1986) (102)
Assembly and activation of HK-PK complex on endothelial cells results in bradykinin liberation and NO formation. (2001) (101)
Factor XII Does not Initiate Prekallikrein Activation on Endothelial Cells (1998) (100)
SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy (2020) (100)
Activation of the contact system of plasma proteolysis in the adult respiratory distress syndrome. (1988) (97)
A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines. (2002) (97)
Low molecular weight kininogen binds to platelets to modulate thrombin-induced platelet activation. (1991) (96)
High-molecular weight kininogen. A secreted platelet protein. (1983) (95)
Murine prolylcarboxypeptidase depletion induces vascular dysfunction with hypertension and faster arterial thrombosis. (2011) (92)
Assembly, activation, and physiologic influence of the plasma kallikrein/kinin system. (2008) (91)
Heparan Sulfate Modulates Kinin Release by Trypanosoma cruzi through the Activity of Cruzipain* (2002) (90)
Bradykinin B2 receptor knockout mice are protected from thrombosis by increased nitric oxide and prostacyclin. (2006) (87)
Thrombotic Microangiopathy in Haematopoietic Stem Cell Transplantation (2012) (86)
Factor XII and uPAR upregulate neutrophil functions to influence wound healing (2018) (85)
High molecular weight kininogen is an inhibitor of platelet calpain. (1986) (85)
High molecular weight kininogen inhibits fibrinogen binding to cytoadhesins of neutrophils and platelets (1989) (84)
Fibrinogen receptors in platelet adhesion to surfaces of extracorporeal circuit. (1987) (80)
Domain 3 of kininogens contains a cell-binding site and a site that modifies thrombin activation of platelets. (1992) (79)
Initiation of Blood Coagulation at Artificial Surfaces (1987) (74)
Assembly and activation of the plasma kallikrein/kinin system: a new interpretation. (2002) (73)
Angiotensin 1-7 and Mas decrease thrombosis in Bdkrb2-/- mice by increasing NO and prostacyclin to reduce platelet spreading and glycoprotein VI activation. (2013) (71)
Reduced thrombosis in Klkb1-/- mice is mediated by increased Mas receptor, prostacyclin, Sirt1, and KLF4 and decreased tissue factor. (2015) (70)
High molecular weight kininogen: localization in the unstimulated and activated platelet and activation by a platelet calpain(s). (1986) (69)
Determination of the bifunctional properties of high molecular weight kininogen by studies with monoclonal antibodies directed to each of its chains. (1987) (69)
Plasma prekallikrein: a risk marker for hypertension and nephropathy in type 1 diabetes. (2003) (68)
Platelet C1- inhibitor. A secreted alpha-granule protein. (1985) (68)
Protease nexin-2/amyloid beta-protein precursor in blood is a platelet-specific protein. (1991) (65)
High molecular weight kininogen binds to platelets by its heavy and light chains and when bound has altered susceptibility to kallikrein cleavage. (1992) (64)
Identification of prolylcarboxypeptidase as the cell matrix‐associated prekallikrein activator (2002) (62)
Interaction of thrombin with PAR1 and PAR4 at the thrombin cleavage site. (2007) (61)
Plasma kallikrein/kinin system: a revised hypothesis for its activation and its physiologic contributions (2000) (60)
Crotalocytin: recognition and purification of a timber rattlesnake platelet aggregating protein. (1980) (60)
Factor XI antigen and activity in human platelets. (1982) (60)
Assay of prekallikrein in human plasma: comparison of amidolytic, esterolytic, coagulation, and immunochemical assays. (1982) (56)
Ordered adsorption of coagulation factor XII on negatively charged polymer surfaces probed by sum frequency generation vibrational spectroscopy (2007) (56)
Effect of negatively charged activating compounds on inactivation of factor XIIa by Cl inhibitor. (1987) (54)
High-molecular-weight kininogen is exclusively membrane bound on endothelial cells to influence activation of vascular endothelium. (1995) (53)
Myeloperoxidase interacts with endothelial cell-surface cytokeratin 1 and modulates bradykinin production by the plasma Kallikrein-Kinin system. (2007) (53)
Mapping Binding Domains of Kininogens on Endothelial Cell Cytokeratin 1* (1999) (52)
Physiologic activities of the contact activation system. (2014) (52)
Identification of prolyl carboxypeptidase as an alternative enzyme for processing of renal angiotensin II using mass spectrometry. (2013) (51)
Synthesis and expression of C1 inhibitor by human umbilical vein endothelial cells. (1989) (51)
Activation of the Plasma Kallikrein/Kinin System on Cells: A Revised Hypothesis (1999) (51)
The carboxyl terminus of bradykinin and amino terminus of the light chain of kininogens comprise an endothelial cell binding domain. (1994) (50)
Prolylcarboxypeptidase promotes angiogenesis and vascular repair. (2013) (49)
Bradykinin regulates the expression of kininogen binding sites on endothelial cells. (1993) (49)
Protease Nexin-2/Amyloid β-Protein Precursor Inhibits Factor Xa in the Prothrombinase Complex (*) (1995) (47)
Crotalocytin: Characterization of the Timber Rattlesnake Platelet Activating Protein (1980) (46)
The contact activation system: biochemistry and interactions of these surface-mediated defense reactions. (1986) (45)
Assembly of High Molecular Weight Kininogen and Activation of Prekallikrein on Cell Matrix (2001) (45)
Mechanisms of Arg-Pro-Pro-Gly-Phe inhibition of thrombin. (2003) (45)
Neonatal purpura fulminans in association with factor V R506Q mutation. (1996) (44)
Membrane expression of platelet calpain (1990) (41)
Potential Role of Protease Nexin‐2/Amyloid β‐Protein Precursor as a Cerebral Anticoagulant a (1992) (40)
Activation of the plasma kallikrein/kinin system on endothelial cells. (1999) (40)
Expression, purification, and characterization of the Kunitz-type proteinase inhibitor domain of the amyloid beta-protein precursor-like protein-2. (1994) (38)
Mapping the Interaction between High Molecular Mass Kininogen and the Urokinase Plasminogen Activator Receptor* (2004) (37)
Factor VLeiden Inhibits Fibrinolysis In Vivo (2004) (37)
The Preparation and Characterization of Novel Peptide Antagonists to Thrombin and Factor VIIa and Activation of Protease-Activated Receptor 1 (2004) (37)
Factor IXa inhibition by protease nexin-2/amyloid beta-protein precursor on phospholipid vesicles and cell membranes. (1995) (36)
Activation of the plasma kallikrein/kinin system on endothelial cell membranes. (1999) (36)
Hemostatic/Fibrinolytic Protein Changes in C3H/HeN Mice Infected with Rickettsia conorii (2000) (35)
Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis (2007) (34)
The thromboprotective effect of bortezomib is dependent on the transcription factor Kruppel-like factor 2 (KLF2). (2014) (34)
AβPP/APLP2 Family of Kunitz Serine Proteinase Inhibitors Regulate Cerebral Thrombosis (2009) (34)
Overexpression of prolylcarboxypeptidase enhances plasma prekallikrein activation on Chinese hamster ovary cells. (2005) (34)
The plasma kallikrein/kinin and renin angiotensin systems in blood pressure regulation in sepsis. (2004) (33)
Expression of platelet C1 inhibitor (1993) (31)
Membrane expression of platelet calpain. (1990) (30)
Plasma kallikrein activates the epithelial sodium channel in vitro but is not essential for volume retention in nephrotic mice (2018) (30)
A method radioimmunoassay of human platelet thrombospondin: Different patterns of thrombospondin and β-thromboglobulin antigen secretion and clearance from the circulation (1985) (29)
Intraoperative monitoring of danaparoid sodium anticoagulation during cardiovascular operations. (1998) (28)
Platelet protease nexin-2/amyloid beta-protein precursor. Possible pathologic and physiologic functions. (1991) (28)
Alpha thalassemia screening in neonates by mean corpuscular volume and mean corpuscular hemoglobin determination. (1973) (27)
Characterization of molecular defects of Fitzgerald trait and another novel high-molecular-weight kininogen-deficient patient: insights into structural requirements for kininogen expression. (2003) (27)
The physiologic basis of assembly and activation of the plasma kallikrein/kinin system (2004) (27)
The Relative Priority of Prekallikrein and Factors XI/XIa Assembly on Cultured Endothelial Cells* (2003) (26)
Factor XI Assembly and Activation on Human Umbilical Vein Endothelial Cells in Culture (2001) (26)
Expression of platelet C1 inhibitor. (1993) (25)
Factor XII Activation Promotes Platelet Consumption in the Presence of Bacterial-Type Long-Chain Polyphosphate In Vitro and In Vivo (2018) (25)
Prolylcarboxypeptidase deficiency is associated with increased blood pressure, glomerular lesions, and cardiac dysfunction independent of altered circulating and cardiac angiotensin II (2017) (25)
Interferon gamma increases in vitro and in vivo expression of C1 inhibitor (1990) (24)
Enhanced Plasmin Inhibition by a Reactive Center Lysine Mutant of the Kunitz-type Protease Inhibitor Domain of the Amyloid β-Protein Precursor (*) (1995) (23)
Concise Guide to Hematology (2011) (23)
Plasma kallikrein enhances platelet aggregation response by subthreshold doses of ADP. (2017) (22)
Plasma contact activation: a revised hypothesis. (1998) (22)
Protease nexin-2/Amyloid beta-protein precursor regulates factor VIIa and the factor VIIa-tissue factor complex. (2000) (21)
Kinetics of inhibition of platelet calpain II by human kininogens. (1990) (21)
Administration of gamma interferon in human subjects decreases plasminogen activation and fibrinolysis without influencing C1 inhibitor. (1994) (21)
Myeloid-related protein-14 regulates deep vein thrombosis. (2017) (21)
Factor XII – What's important but not commonly thought about (2019) (21)
Radioimmunoassay of human platelet thrombospondin: different patterns of thrombospondin and beta-thromboglobulin antigen secretion and clearance from the circulation. (1985) (20)
Domain 2 of uPAR regulates single-chain urokinase-mediated angiogenesis through β1-integrin and VEGFR2. (2013) (20)
The Williams-Beuren Syndrome—A Window into Genetic Variants Leading to the Development of Cardiovascular Disease (2012) (20)
Oral thrombostatin FM19 inhibits prostate cancer (2010) (19)
Kininogen-cytokeratin 1 interactions in endothelial cell biology. (1999) (18)
Thrombostatin, a bradykinin metabolite, reduces platelet activation in a model of arterial wall injury. (2002) (18)
Plasma Prekallikrein: Its Role in Hereditary Angioedema and Health and Disease (2018) (18)
A Cross-sectional Study of KLKB1 and PRCP Polymorphisms in Patient Samples with Cardiovascular Disease (2016) (18)
A Novel Antithrombotic Mechanism Mediated by the Receptors of the Kallikrein/Kinin and Renin–Angiotensin Systems (2016) (17)
Thrombostatin Inhibits Cyclic Flow Variations in Stenosed Canine Coronary Arteries (2001) (17)
Antithrombotic potential of the contact activation pathway (2016) (17)
Mapping the interaction of bradykinin 1–5 with the exodomain of human protease activated receptor 4 (2005) (16)
Alzheimer disease is in part a thrombohemorrhagic disorder (2016) (16)
Assessment of whole blood coagulation with a microfluidic dielectric sensor (2018) (15)
Dural sinus thrombosis with abnormalities of protein S and fibrinogen. (1990) (15)
Prolylcarboxypeptidase independently activates plasma prekallikrein (fletcher factor). (2014) (15)
Streptococcal inhibitor of complement-mediated lysis (SIC): an anti-inflammatory virulence determinant. (2010) (15)
Ponatinib and other CML Tyrosine Kinase Inhibitors in Thrombosis (2020) (14)
Plasma prekallikrein assay: reversible inhibition of C-1 inhibitor by chloroform and its use in measuring prekallikrein in different mammalian species. (1984) (14)
Novel anti-thrombotic mechanisms mediated by Mas receptor as result of balanced activities between the kallikrein/kinin and the renin-angiotensin systems (2020) (14)
Factor XII: New life for an old protein (2010) (14)
Left ventricular thrombus with normal left ventricular function and hyperaggregable platelets in a patient with polycystic disease of multiple organs. (1984) (13)
Elevated neutrophil-lymphocyte ratio predicts mortality following elective endovascular aneurysm repair. (2019) (13)
Association of the prothrombin G20210A mutation with factor V Leiden in a midwestern American population. (2000) (13)
The rate of fibrinopeptide B release modulates the rate of clot formation: a study with an acquired inhibitor to fibrinopeptide B release (1991) (13)
Recombinant Kunitz Protease Inhibitory Domain of the Amyloid β-Protein Precursor as an Anticoagulant in Venovenous Extracorporeal Circulation in Rabbits (1999) (13)
The pharmacokinetics of the kininogens. (1998) (13)
Potential role of protease nexin-2/amyloid beta-protein precursor as a cerebral anticoagulant. (1992) (12)
Acquired Hemophilia A After Nivolumab Therapy in a Patient With Metastatic Squamous Cell Carcinoma of the Lung Successfully Managed With Rituximab. (2019) (12)
Platelet forms of plasma proteins: plasma cofactors/substrates and inhibitors contained within platelets. (1985) (12)
Ponatinib treatment promotes arterial thrombosis and hyperactive platelets. (2019) (12)
Extracorporeal Circulation Without Bleeding (2014) (12)
Plasma Prekallikrein Is Associated With Carotid Intima-Media Thickness in Type 1 Diabetes (2015) (11)
Effect of Lanadelumab on Coagulation Parameters in Patients With Hereditary Angioedema: Findings From The Phase 3 HELP Study: 121 (2019) (10)
Transferrin: a blood coagulation modifier (2020) (10)
Quantitation and characterization of human platelet glycoprotein IIIa by radioimmunoassay. (1987) (10)
PPACK-thrombin is a noncompetitive inhibitor of α-thrombin binding to human platelets (1992) (10)
Von Willebrand factor promoter targets the expression of amyloid β protein precursor to brain vascular endothelial cells of transgenic mice (2003) (9)
Laser-light scattering, a new method for continuous monitoring of platelet activation in circulating fluid. (2003) (9)
Crotalocytin: characterization of the timber rattlesnake platelet activating protein. (1980) (9)
Thrombostatin FM compounds: direct thrombin inhibitors – mechanism of action in vitro and in vivo (2008) (9)
Synthesis of Novel Peptide Inhibitors of Thrombin‐induced Platelet Activation (2006) (9)
Role of the renin-angiotensin system in the development of severe COVID-19 in hypertensive patients (2020) (9)
Platelet high-molecular-weight kininogen. (1989) (9)
Sweet and sticky: diabetic platelets, enhanced reactivity, and cardiovascular risk. (2007) (9)
Nomenclature of factor XI and the contact system (2019) (9)
Insights on Monoclonal Antibodies to Kininogens' Heavy Chain Which Influence Kininogens' Binding to Platelets (1992) (8)
Homonymous hemianopia caused by occipital lobe infarction in heparin-induced thrombocytopenia and thrombosis syndrome. (2005) (8)
The hereditary angioedema syndromes. (2018) (8)
Abstracts from the 10th C1-inhibitor deficiency workshop (2017) (8)
Aprotinin: can its benefits be offset by harmful effects? (1997) (7)
Disseminated Intravascular Coagulation: Pathogenesis and Management (1991) (7)
Modulation of the cell membrane expression of the kininogens regulates the rate of bradykinin delivery to cells. (1992) (7)
PPACK-thrombin is a noncompetitive inhibitor of alpha-thrombin binding to human platelets. (1992) (7)
Venous and Arterial Thrombosis (2014) (7)
Elevated Neutrophil to Lymphocyte Ratio is Associated with Worse Outcomes after Carotid Endarterectomy in Asymptomatic Patients. (2021) (6)
A targetable pathway in neutrophils mitigates both arterial and venous thrombosis (2022) (6)
Gene Expression, Regulation and Cell Surface Presentation of the Kininogens (1997) (6)
Hematology for the Medical Student (2003) (6)
Factor XII Promotes Leukocyte Inflammation and Its Deficiency Results in Faster Wound Healing (2011) (6)
Gamma interferon administration to patients with atopic dermatitis inhibits fibrinolysis and elevates C1 inhibitor. (1998) (6)
Phosphatase 2A participates in interferon-gamma's induced upregulation of C1 inhibitor mRNA expression. (1996) (6)
Pseudohypoxemia due to leukemia and thrombocytosis. (1980) (6)
Developing peptide inhibitors to thrombin activation of platelets from bradykinin analogs. (2001) (6)
Short term efficacy of recombinant porcine factor VIII in patients with factor VIII inhibitors (2020) (5)
Von Willebrand factor promoter targets the expression of amyloid beta protein precursor to brain vascular endothelial cells of transgenic mice. (2003) (5)
Ponatinib and Cardiovascular Complications (2016) (5)
Are maternal antiplatelet antibodies a prothrombotic condition leading to miscarriage? (2011) (5)
Polyphosphate expression by cancer cell extracellular vesicles mediates binding of factor XII and contact activation (2021) (5)
A Platelet Acquired Storage Pool Disorder Associated with Tamoxifen Therapy (2012) (5)
Elevated neutrophil to lymphocyte ratio is associated with decreased amputation-free survival after femoropopliteal percutaneous revascularization. (2021) (5)
Interferon gamma increases in vitro and in vivo expression of C1 inhibitor. (1990) (4)
A classification of disorders of hemostasis and thrombosis in patients with malignancy. (1982) (4)
Vascular Disease Patient Information Page: COVID–19-related thrombosis (2020) (4)
A Novel Point-of-Care Whole Blood Coagulation Assay to Monitor Emicizumab Therapy in Patients with Hemophilia (2018) (4)
Venous Thromboembolism Chemoprophylaxis in Total Hip and Knee Arthroplasty: A Critical Analysis Review (2019) (4)
Bilateral, multiple, episodic retinal vein occlusions associated with common variable immunodeficiency. (2015) (3)
Plasma coagulation proteases, proteolytic inhibitors, and their interaction with platelets. (1982) (3)
Factitious heparin administration. (1981) (3)
Diabetic Platelets, Enhanced Reactivity, and Cardiovascular Risk* (2007) (3)
Over-Expression of Prolylcarboxypeptidase Enhances Plasma Prekallikrein Activation on Chinese Hamster Ovary Cell Membranes. (2005) (3)
Why do we want to know how factor XII levels are modulated? (2010) (3)
Thrombosis in flowing blood. (2009) (3)
Electronically determined red cell indices in a predominantly black urban population of children 4 to 8 years of age. (1974) (3)
High molecular weight kininogen binds to neutrophils. (1989) (3)
Mice Deficient in ß2-Glycoprotein I Have a Delayed Time to Thrombosis (2019) (3)
Prolylcarboxypeptidase Murine Hypomorphs Are Hypertensive and Prothrombotic (2008) (3)
Review: The plasma kallikrein/kinin and renin angiotensin systems in blood pressure regulation in sepsis (2004) (3)
Poly (acrylic acid) (PAA) is a contact system activator with properties to stop hemorrhage. (2020) (3)
Serpin targets in hemostasis/kinin formation. (2019) (3)
A Miniaturized Microfluidic Dielectric Sensor for Point-of-Care Assessment of Blood Coagulation (2016) (2)
Prolylcarboxypeptidase Promotes Endothelial Cell Proliferation and Vascular Repair (2011) (2)
Expression of Platelet C 1 Inhibitor (2003) (2)
receptor, prostacyclin, Sirt1 and KLF4 and decreased tissue factor mice is mediated by increased Mas -/- Klkb1 Reduced thrombosis in (2014) (2)
Oscar D. Ratnoff: A man for all seasons (2010) (2)
Prekallikrein and Plasma Kallikrein (2013) (2)
Neutrophil KLF2 Regulates Arterial and Venous Thrombosis (2018) (2)
Amyloid β-protein precursor: A new anticoagulant? (1997) (2)
Acquired Dysfibrinogenemia Krakow III after Everolimus Therapy (2019) (2)
The amyloid beta-precursor protein-The unappreciated cerebral anticoagulant. (2017) (2)
Abstract 630: Blood Pressure and Kidney Function in PRCP deficient Mice (2013) (2)
THROMBOSIS AND HEMOSTASIS The thromboprotective effect of bortezomib is dependent on the transcription factor Kruppel-like factor 2 ( KLF 2 ) (2014) (2)
Outcomes of Immune Thrombotic Thrombocytopenic Purpura (iTTP) With Upfront Cyclophosphamide vs. Rituximab (2020) (2)
Inhibitors of Thrombin and Factor Xa (2000) (2)
Factor V Inhibits Fibrinolysis In Vivo (2004) (2)
THROMBOSIS AND HEMOSTASIS Angiotensin 1-7 and Mas decrease thrombosis in Bdkrb 2 2 / 2 mice by increasing NO and prostacyclin to reduce platelet spreading and glycoprotein VI activation (2013) (2)
Hematology grants workshop. (2002) (2)
Transmission of lupus anticoagulant by allogeneic stem cell transplantation (2014) (2)
Coagulation Factor XIIa (2013) (1)
PolyP's many faces. (2016) (1)
Heparin versus hirudin for acute coronary syndromes. (1997) (1)
Comprar Concise Guide To Hematology | Alvin H. Schmaier | 9781405196666 | Wiley (2011) (1)
Thrombostatin Fm19 ‐ A Thrombin Receptor Activation Antagonist (2007) (1)
Abnormalities in coagulation (2012) (1)
Myeloid Cell Physiology and Disorders (2011) (1)
Bradykinin – An elusive peptide in measuring and understanding (2022) (1)
Overview of Hemostasis (2011) (1)
The Urokinase Plasminogen Activator Receptor Mediates ScuPA- or FXII-Induced Cell Growth and Proliferation through ERK1/2, Akt, and Beta-1-Integrin. (2006) (1)
Platelet Protease Nexin‐2/Amyloid β‐Protein Precursor (1991) (1)
Thrombosis Prevention without Anticoagulation (2014) (1)
Chapter 637 – Coagulation Factor XIIa (2013) (1)
Contact ignition by single-chain XIIa. (2017) (1)
Alzheimer's disease and beta-amyloid. (1992) (1)
THROMBOSIS AND HEMOSTASIS Reduced thrombosis in Klkb 1 2 / 2 mice is mediated by increased Mas receptor , prostacyclin , Sirt 1 , and KLF 4 and decreased tissue factor (2015) (1)
Bradykinin B2 Receptor KO Mice Are Protected From Thrombosis by A Platelet Spreading Defect (2010) (1)
Medically-induced hemophilia C to treat thrombosis. (2015) (1)
Disseminated intravascular coagulation. (1999) (1)
Characterization of cell binding and thrombin inhibitory regions on kininogens' heavy chain. (1992) (0)
The Contributions of the P4-P2 Positions in PAR1 and 4 for Thrombin Recognition and Cleavage. (2005) (0)
Characterization of Clustered CTCs to Eliminate Breast Cancer Metastasis (2019) (0)
Correction to: Concise Guide to Hematology (2019) (0)
Physiology of Hemostasis (2018) (0)
Vascular surgery patients with elevated neutrophil-to-lymphocyte ratios have downregulated neutrophil complement RNA expression (2022) (0)
Abstract 037: Coagulation Factor XII Promotes Platelet Consumption in the Presence of Microbial Polyphosphate Under Shear Flow (2018) (0)
Human alpha thrombin inhibited by RPPGF and hirugen (2003) (0)
Abstract 39: Myeloid Klf2 Regulates Arterial and Venous Thrombosis (2017) (0)
Effect of the Neutrophil/Lymphocyte Ratio on Outcome after Carotid Endarterectomy and Carotid Artery Disease Progression (2020) (0)
Mapping the Interaction of Peptide RPPGF with the Exodomain on Human Protease Activated Receptor 4 (PAR4). (2004) (0)
Prospective Evaluation of the Effects of Neutrophil-lymphocyte Ratio on Mortality after Elective Vascular Surgical Procedures (2021) (0)
Thrombosis and Anticoagulation (2011) (0)
Mapping the interaction between uPAR and high molecular weight kininogen (2003) (0)
Scupa Or Fxii Stimulate Erk1/2 Or Akt Through Upar And Beta 1 Integrins (2007) (0)
Amyloid beta-protein precursor: a new anticoagulant? (1997) (0)
Case Report: Unmasked Inherited Dysfibrinogenemia After Everolimus Therapy (2020) (0)
Factor XII Deficiency or Hageman Factor Deficiency (2014) (0)
with hypertension and faster arterial thrombosis Murine prolylcarboxypeptidase depletion induces vascular dysfunction (2012) (0)
Angiotensin Receptor 2 Over-Expression: A Novel Physiologic Mechanism for Thrombosis Protection. (2004) (0)
Thrombostatin inhibits cyclic flow variations in the folts model of canine coronary artery thrombosis (2000) (0)
Proteomic and Metabolomic Approaches to Cell Physiology and Pathophysiology Identification of prolyl carboxypeptidase as an alternative enzyme for processing of renal angiotensin II using mass spectrometry (2013) (0)
Factor XII’s autoactivation and cell biology interdigitate in disease states (2020) (0)
Subclinical Acute Kidney Injury in COVID-19: Possible Mechanisms and Future Perspectives (2022) (0)
Introduction to Hematology (2011) (0)
A 754 2 3 J U L Y 2 0 0 9 I V O L U M E 1 1 4 , N U M B E R 4 Blood (0)
COAGULATION factors. (1953) (0)
Vascular Endothelial Cells Produce Coagulation Factors That Control Their Growth via Joint Protease-Activated Receptor and C5a Receptor 1 (CD88) Signaling. (2022) (0)
activator receptor on endothelial cells Expression and colocalization of cytokeratin 1 and urokinase plasminogen (2010) (0)
Outcomes after Treatment with Upfront Cyclophosphamide or Rituximab for Initial Acquired Thrombotic Thrombocytopenic Purpura (2019) (0)
Editorial: Introduction to the Presentations at the Factor XI and the Contact System SSC Session of the ISTH, Montpellier, France, May 27, 2016 (2017) (0)
THE PREPARATION AND CHARACTERIZATION OF NOVEL PEPTIDE ANTAGONISTS TO THROMBIN, FACTOR VIIa AND ACTIVATION OF PROTEASE ACTIVATED RECEPTOR1 § (2004) (0)
Approach to the Bleeding Patient (2011) (0)
Leukocyte XII Regulates Venous Thrombosis Risk (2015) (0)
Bradykinin Is a Proximal Event in Experimental Cerebral Malaria (2021) (0)
Best of ASH in Hemostasis and Thrombosis 1 (2018) (0)
489: USE OF COAGULATION FACTOR XA (RECOMBINANT), INACTIVATED-ZHZO (RFXAI) IN CLINICAL PRACTICE (2019) (0)
increased nitric oxide and prostacyclin Bradykinin B2 receptor knockout mice are protected from thrombosis by (2013) (0)
OC-06 The molecular mechanisms of ponatinib-induced thrombosis (2021) (0)
Thrombosis Protection In Klkb1-/- (Prekallikrein KO) Mice Is Mediated By Increased Renal Mas Receptor, Plasma Prostacyclin, and Aortic Sirt1 (2013) (0)
Outside-In Signaling upon Assembly on Endothelial Cells of the Proteins of the Plasma Kallikrein/Kinin System. (2005) (0)
Atlas of Hematology Slides (2011) (0)
Prolylcarboxypeptidase Deficiency Is a Risk Factor for Arterial Thrombosis and Hypertension (2010) (0)
Introduction to current issue. (2017) (0)
Over-Expression of the Mas Receptor Decreases Arterial Thrombosis Risk in B2R KO Mice by Elevating NO and Prostacyclin and Reducing GPVI Activation (2011) (0)
Prolylcarboxypeptidase Is a Risk Factor for Cardiovascular Events (2014) (0)
Editoral Physiologic Activities of the Contact Activation System (2014) (0)
Unique Thrombotic and Hemostatic Complications Associated with Allogeneic Hematopoietic Stem Cell Transplantation (2010) (0)
Downregulation of Classic Complement Pathway Genes in Patients with Elevated Neutrophil-lymphocyte Ratio (2021) (0)
Editorial: Proceedings of KININ2018CLE, Cleveland, Ohio, June 18-20, 2018: A Compendium of the Presentations (2019) (0)
cell membranes plasminogen activator receptor, gC1qR, and cytokeratin 1 on endothelial Factor XII interacts with the multiprotein assembly of urokinase (2013) (0)
Persistent disseminated intravascular coagulation despite correction of endoleaks after thoracoabdominal endovascular aneurysm repair (2021) (0)
Discovery of new renal Ang II processing enzyme activity using mass spectrometry and gene deletion mouse models (2013) (0)
inhibitor Interferon gamma increases in vitro and in vivo expression of C1 (2011) (0)
kininogen and delays thrombosis ) causes loss of plasma mKng1 Deletion of murine kininogen gene 1 ( (2008) (0)
130: OFF-PUMP CORONARY ARTERY BYPASS IN A PATIENT WITH INHERITED FACTOR V DEFICIENCY (2018) (0)
Severe Subconjunctival Hemorrhage After Intravitreal Injection in a Patient With Hemophilia A (2023) (0)
Editorial: Kinin 2022 Meeting, Annecy, France (2023) (0)
Abstract 091: Coagulation Factor XII Promotes Platelet Consumption in the Presence of Microbial Polyphosphate Under Shear Flow (2018) (0)
Recent studies indicate that assembly of high molecular weight kininogen on its multiprotein receptor allows for prekallikrein activation. On endothelial cells, factor XII activa- tion is secondary to prekallikrein activation and amplifies it. The immediate consequence of plasma prekallikrein activa (0)
Exosome Polyphosphate Mediates the Activation of FXII By Cancer Cell-Derived Exosomes (2018) (0)
Prolylcarboxypeptidase deficiency is associated with increased blood pressure, glomerular lesions, and cardiac dysfunction independent of altered circulating and cardiac angiotensin II (2017) (0)
kininogen and delays thrombosis Deletion of murine kininogen gene 1 (mKng1) causes loss of plasma (2013) (0)
The Prothrombin G20210A Mutation and Factor V Leiden Mutation in Patients With Cerebrovascular Disease (2017) (0)
Structure of Thrombin Bound to the Inhibitor FM19 (2008) (0)
Protection of β2GPI Deficient Mice from Thrombosis May Reflect a Platelet Activation Defect (2021) (0)
Alzheimer's disease and beta-amyloid. (1992) (0)
Leukocyte Factor XII Mediates Inflammation and Its Deficiency Promotes Wound Healing (2012) (0)
High Molecular Weight Kininogen Inhibits Fibrinogen Binding to Cytoadhesins of Neutrophfls and Platelets (2002) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Alvin H. Schmaier?

Alvin H. Schmaier is affiliated with the following schools: